ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Chinese-AstraZeneca cancer cure joint venture raises $100m

Public-private Dizal Pharma to boost R&D and domestic footprint

A technician inspects anti-cancer drugs at a laboratory in Lianyungang, Jiangsu Province.    © Reuters

SHANGHAI -- Dizal Pharmaceutical, a joint venture between China's state-owned SDIC Fund Management, AstraZeneca and Zytz Partners, has announced the closing of a $100 million financing round led by Lilly Asia Ventures.

New investors Sequoia Capital China, Trinity Innovation Fund and Wuxi NewForce Fund also participated in the round, according to a company statement on Wednesday.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more